Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 8:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: nicotinamide riboside Clear all
Not listed Phase 1 Interventional

Basis: Evaluating Sirtuin Supplements To Benefit Elderly Trauma Patients (BES2T BET)

NCT03635411
View directory record Official record
Conditions
Recovery of Function
Interventions
Nicotinamide Riboside and Pterostilbene, Placebo
Dietary Supplement
Lead sponsor
Elysium Health
Industry
Eligibility
65 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2020 · Synced Sep 9, 2026, 8:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Protective Effect of Nicotinamide Riboside Against Acetaminophen Toxicity

NCT06214468
View directory record Official record
Conditions
Drug Toxicity
Interventions
Acetaminophen and Nicotinamide Riboside, Acetaminophen
Combination Product · Drug
Lead sponsor
University of South Alabama
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 9, 2026, 8:32 AM EDT
Active, not recruiting Phase 2 Interventional

NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy

NCT04112641
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
Nicotinamide riboside, Placebo capsules
Drug
Lead sponsor
Donna Hammond, PhD
Other
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 9, 2026, 8:32 AM EDT
Completed Not applicable Interventional Results available

Study to Evaluate the Effect of Nicotinamide Riboside on Immunity

NCT02812238
View directory record Official record
Conditions
Atherosclerosis, Diabetes, Coronary Artery Disease
Interventions
Nicotinamide riboside (NR), Placebo
Dietary Supplement · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 39 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Sep 9, 2026, 8:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Protection From Acute Kidney Injury (AKI) With Basis™ Treatment

NCT04342975
View directory record Official record
Conditions
AKI
Interventions
Nicotinamide Riboside + Pterostilbene, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Sep 9, 2026, 8:32 AM EDT
Recruiting Not applicable Interventional

Mechanistic Study of Nicotinamide Riboside on NAD+ Biology in Individuals With Combined Pulmonary Hypertension

NCT07563322
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Nicotinamide Riboside (NR), Placebo
Dietary Supplement · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 9, 2026, 8:32 AM EDT
Completed Phase 4 Interventional Results available

Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19

NCT04809974
View directory record Official record
Conditions
Covid19, Sequelae of; Infection, Cognitive Symptom
Interventions
Niagen
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 9, 2026, 8:32 AM EDT
Recruiting Early Phase 1 Interventional

Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation

NCT04332341
View directory record Official record
Conditions
Allogeneic Hematopoietic Cell Transplantation
Interventions
Nicotinamide riboside (NR)
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 9, 2026, 8:32 AM EDT
Completed Phase 3 Interventional Results available

Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease

NCT03743636
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Nicotinamide riboside, Resveratrol, Placebo
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Sep 9, 2026, 8:32 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants

NCT04614714
View directory record Official record
Conditions
Preterm Birth, Inadequate Milk Production
Interventions
Nicotinamide Riboside (NR), Placebo
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 9, 2026, 8:32 AM EDT
Recruiting Phase 2 Interventional

Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors

NCT05194397
View directory record Official record
Conditions
Lymphoblastic Leukemia, Cancer Survivors, Aplastic Anemia, Myelodysplastic Syndromes, Myeloid Leukemia
Interventions
Nicotinamide Riboside, Placebo, Exercise Intervention
Dietary Supplement · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years to 30 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Duarte, California • Philadelphia, Pennsylvania • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 9, 2026, 8:32 AM EDT
Active, not recruiting Early Phase 1 Interventional

Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure

NCT04528004
View directory record Official record
Conditions
Heart Failure, Systolic, Heart Failure NYHA Class IV, Metabolic Disturbance
Interventions
Nicotinamide riboside, Placebo
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 9, 2026, 8:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment

NCT03482167
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Niagen®, Placebo
Drug · Other
Lead sponsor
University of Delaware
Other
Eligibility
60 Years to 90 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 9, 2026, 8:32 AM EDT
Recruiting Phase 2 Interventional

Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis

NCT06567717
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Zinc, Placebos for zinc and nicotinamide riboside, Nicotinamide riboside
Drug · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 9, 2026, 8:32 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Validation of NAD+ Measurements for Human Clinical Studies

NCT07416786
View directory record Official record
Conditions
Healthy Adults
Interventions
Oral NR Supplementation
Dietary Supplement
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 110 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 9, 2026, 8:32 AM EDT
Completed Phase 1Phase 2 Interventional

NAD Supplementation and Vascular Health in PAD

NCT06534944
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Nicotinamide riboside
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
55 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 9, 2026, 8:32 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety & Efficacy of Nicotinamide Riboside Supplementation for Improving Physiological Function in Middle-Aged and Older Adults

NCT02921659
View directory record Official record
Conditions
Aging
Interventions
Niagen™, Placebo
Dietary Supplement
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
55 Years to 79 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Sep 9, 2026, 8:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

"Pharmacokinetic Study of Nicotinamide Riboside"

NCT02689882
View directory record Official record
Conditions
Metabolic Disturbance
Interventions
nicotinamide riboside
Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Sep 9, 2026, 8:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Use of 31P MRS to Assess Brain NAD+ in Healthy Current and Former Collegiate Athletes

NCT02721537
View directory record Official record
Conditions
Concussion, Mild
Interventions
Nicotinamide Riboside, Matching placebo
Dietary Supplement · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
2
States / cities
Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Sep 9, 2026, 8:32 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy

NCT05590468
View directory record Official record
Conditions
Mitochondrial Myopathy
Interventions
Nicotinamide Riboside, Placebo
Dietary Supplement · Drug
Lead sponsor
Ralitza Gavrilova
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 9, 2026, 8:32 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus

NCT06032923
View directory record Official record
Conditions
Systemic Lupus Erythematosus (Sle)
Interventions
Nicotinamide Riboside
Dietary Supplement
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 120 Years · Female only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 9, 2026, 8:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration

NCT03912220
View directory record Official record
Conditions
Small Fiber Neuropathy
Interventions
Nicotinamide riboside, Placebo Oral Tablet
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Sep 9, 2026, 8:32 AM EDT
Active, not recruiting Phase 2 Interventional

Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD

NCT04040959
View directory record Official record
Conditions
Vascular Diseases, Kidney Disease, Blood Pressure, Oxidative Stress
Interventions
Nicotinamide riboside
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
35 Years to 80 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 9, 2026, 8:32 AM EDT
Completed Phase 2 Interventional Results available

Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection

NCT04818216
View directory record Official record
Conditions
SARS-CoV-2 Infection, Acute Kidney Injury
Interventions
Placebo, Nicotinamide riboside
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
New York, New York • San Antonio, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 25, 2023 · Synced Sep 9, 2026, 8:32 AM EDT